U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially ...

Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.

Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

Investing.com -- Moderna , Inc. (NASDAQ: MRNA) shares surged 14% following remarks by Oracle (NYSE: ORCL) Chairman Larry ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S.